VRML - バ―ミリオン (Vermillion Inc.)

VRMLのニュース

   Vermillion : Set to Join Russell 3000 Index | MarketScreener  2020/06/11 07:38:15 MarketScreener
Vermillion Set to Join Russell 3000® Index AUSTIN, Texas - June 9, 2020 - Vermillion, Inc. , a bioanalytical-based women's health company focused on… | June 11, 2020
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   Vermillion : Reports First Quarter 2020 Financial Results | MarketScreener  2020/06/02 13:26:11 MarketScreener
Vermillion Reports First Quarter 2020 Financial Results Conference Call scheduled for today, May 14th at 4:30 p.m. ET AUSTIN, Texas - May… | June 2, 2020
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women  2019/12/17 13:00:00 Business Wire
AUSTIN, Texas & PHILADELPHIA--(BUSINESS WIRE)-- #OVA1--Vermillion, Inc. and Einstein Medical Center announced first patient enrolled in study for detection of ovarian cancer risk in African American women.
   GenomeSmartTM and ASPiRA LABS®, a Vermillion Company, Launch Pilot Program to Improve Access to Genetic Testing  2019/12/03 11:00:00 Business Wire
LOS ALTOS, Calif. & AUSTIN, Texas--(BUSINESS WIRE)-- #GeneticTesting--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, today announced a pilot program with ASPiRA LABS®, a Vermillion company (Nasdaq: VRML), where GenomeBrainTM will be offered to a select group of providers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to th
   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:48:08 Seeking Alpha
Vermillion, Inc. (NASDAQ:VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri – President and Chief Executive Of
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women  2019/12/17 13:00:00 Business Wire
AUSTIN, Texas & PHILADELPHIA--(BUSINESS WIRE)-- #OVA1--Vermillion, Inc. and Einstein Medical Center announced first patient enrolled in study for detection of ovarian cancer risk in African American women.
   GenomeSmartTM and ASPiRA LABS®, a Vermillion Company, Launch Pilot Program to Improve Access to Genetic Testing  2019/12/03 11:00:00 Business Wire
LOS ALTOS, Calif. & AUSTIN, Texas--(BUSINESS WIRE)-- #GeneticTesting--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, today announced a pilot program with ASPiRA LABS®, a Vermillion company (Nasdaq: VRML), where GenomeBrainTM will be offered to a select group of providers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to th
   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:48:08 Seeking Alpha
Vermillion, Inc. (NASDAQ:VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri – President and Chief Executive Of

calendar